Sinew Pharma Inc. (6634.TWO)
TWD 47.0
(1.51%)
TWD 47.0
(1.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -118.04 Thousand | -93.76 Million | -57.31 Million | -59.26 Million | -58.73 Million |
| Net Income | -170.92 Thousand | -140.18 Million | -91.57 Million | -82.01 Million | -76.22 Million |
| Depreciation & Amortization | 28.98 Thousand | 22.81 Million | 22.64 Million | 21.85 Million | 18.25 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 17.99 Thousand | 16.7 Million | 12.09 Million | 2.07 Million | 3.32 Million |
| Change in working capital | 6748.00 | 7.34 Million | -71 Thousand | -1.19 Million | -4.09 Million |
| Other non-cash items | -858.00 | -8.09 Million | -2.8 Million | -2.08 Million | -603 Thousand |
| Investing Cash Flow | 26.2 Thousand | -221.14 Million | -648.56 Million | -256.72 Million | 34.01 Million |
| Investments in PPE | -7214.00 | -5.88 Million | -5.86 Million | -2.69 Million | -6.66 Million |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -135.2 Million | -437.6 Million | -740 Million | -290 Million | -9.99 Million |
| Sales/Maturities of investments | 171 Million | 224.6 Million | 100 Million | 38.5 Million | 51.2 Million |
| Other Investing Activities | 33.41 Thousand | -2.26 Million | -2.69 Million | -2.52 Million | -535 Thousand |
| Financing Cash Flow | 11.97 Thousand | 10.41 Million | 1.21 Billion | 110.09 Million | 235.65 Million |
| Debt repayment | -6103.00 | -2760.00 | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 18.08 Million | 13.17 Million | 1.21 Billion | 111.92 Million | 236.5 Million |
| Other Financing Activities | 18.08 Thousand | 13.17 Thousand | - | - | 99 Thousand |
| Accounts receivables | 225 Thousand | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | 6748.00 | 7673.00 | - | - | - |
| Cash at beginning of period | 246.67 Thousand | 551.17 Million | 46.82 Million | 252.71 Million | 41.78 Million |
| Cash at end of period | 166.8 Thousand | 246.67 Million | 551.17 Million | 46.82 Million | 252.71 Million |
| Capital Expenditure | -7214.00 | -5.88 Million | -5.86 Million | -2.69 Million | -6.66 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -79.86 Thousand | -304.49 Million | 504.34 Million | -205.89 Million | 210.93 Million |
| Free Cash Flow | -125.26 Thousand | -99.64 Million | -63.18 Million | -61.95 Million | -65.39 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -36.93 Thousand | -36.93 Thousand | -52.3 Thousand | -52.3 Thousand | -33.15 Thousand | -33.15 Thousand |
| Depreciation & Amortization | 7590.00 | 7590.00 | 7512.50 | 7512.50 | 6980.00 | 6980.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 5080.50 | 5080.50 | 6147.00 | 6147.00 | 2852.00 | 2852.00 |
| Change in working capital | -5135.00 | -5135.00 | 7129.00 | 7129.00 | -3755.00 | -3755.00 |
| Other non-cash items | -467.50 | -467.50 | -217.50 | -217.50 | -211.50 | -211.50 |
| Investing Cash Flow | 731.00 | 731.00 | 11.02 Thousand | 11.02 Thousand | 2072.00 | 2072.00 |
| Investments in PPE | -3.73 Million | - | -2440.50 | -2440.50 | -1166.50 | -1166.50 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -130 Million | - | - | - | - | - |
| Sales/Maturities of investments | 135.2 Million | - | - | - | - | - |
| Other Investing Activities | 731.00 | 731.00 | 13.46 Thousand | 13.46 Thousand | 3238.50 | 3238.50 |
| Financing Cash Flow | 317.50 | 317.50 | 1479.00 | 1479.00 | 4510.00 | 4510.00 |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 3.81 Million | - | - | - | - | - |
| Other Financing Activities | 317.50 | 317.50 | 1479.00 | 1479.00 | 4510.00 | 4510.00 |
| Accounts receivables | -1.98 Million | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -5135.00 | -5135.00 | 7129.00 | 7129.00 | -3755.00 | -3755.00 |
| Cash at beginning of period | 166.8 Million | - | - | 205.25 Thousand | 225.96 Thousand | - |
| Cash at end of period | -28.82 Thousand | -28.82 Thousand | -19.22 Thousand | 186.03 Thousand | 205.25 Thousand | -20.71 Thousand |
| Capital Expenditure | -3.73 Million | - | -2440.50 | -2440.50 | -1166.50 | -1166.50 |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -166.83 Million | -28.82 Thousand | -19.22 Thousand | -19.22 Thousand | -20.71 Thousand | -20.71 Thousand |
| Free Cash Flow | -3.76 Million | -29.86 Thousand | -34.17 Thousand | -34.17 Thousand | -28.45 Thousand | -28.45 Thousand |
PANW
CDTAF
FEDFINA
MNPR
CCNEP
TMUS